Clinical stage biopharmaceutical company Acurx Pharmaceuticals Inc (NASDAQ: ACXP), a specialist in antibiotics for challenging bacterial infections, on Monday announced the presentation of Phase 2 clinical trial results for ibezapolstat (IBZ) in Clostridioides difficile Infection (CDI).
The findings, presented at the 17th Biennial Congress of the Anaerobe Society of the Americas, highlighted favorable changes in gut microbiome, including increased Actinobacteria levels in IBZ-treated patients.
Dr Taryn A. Eubank from the University of Houston College of Pharmacy presented the results, affirming IBZ's clinical efficacy in treating CDI. The company plans to advance IBZ into international Phase 3 trials following successful FDA End-of-Phase 2 discussions and Phase 3 readiness. The trials will assess IBZ's clinical cure and potential to reduce CDI recurrence.
Acurx Pharmaceuticals focuses on developing novel antibiotics targeting Gram-positive bacteria, addressing critical unmet needs in infectious diseases.
Sanofi and J&J discontinue phase 3 study of E. coli vaccine candidate
OnCusp Therapeutics' CUSP06 receives US FDA Fast Track Designation
MimiVax reports positive interim analysis of SurVaxM Phase 2b clinical trial
Akeso enrols first patient in cadonilimab Phase 3 clinical trial
NKGen Biotech receives US FDA Fast Track designation for troculeucel in Alzheimer's treatment
Neuphoria Therapeutics to receive USD15m milestone payment from Merck
TriNetX and Fujitsu form joint venture to enhance clinical research in Japan
Royalty Pharma to invest up to USD250m in Biogen's lupus treatment
Lundbeck receives FDA Fast Track designation for amlenetug in multiple system atrophy
Lytix Biopharma secures US patent allowance for LTX-315 clinical programme
GenSight Biologics reports positive five-year resultsfor LUMEVOQ gene therapy
IXICO's AI platform validated in Huntington's Disease research
ILIKOS Consulting partners with Jordan Center for Pharmaceutical Research
Spinogenix reveals topline results from Phase 2 study in Fragile X syndrome
Moleculin's Phase 3 R/R AML pivotal trial receives first European country recruitment approval